Insights
Insights From Our Experts
Articles
Under the Biden Team & Beyond COVID … What Lies Ahead for Healthcare
While the obvious healthcare focus for the new Biden/Harris Administration will be on controlling the COVID-19 pandemic, it’s a critical time to assess what lies beyond COVID for their attention. To gain a sense of what’s…
Transforming Commercialization With Industry-Leading Partnerships
Healthcare innovation is being intensified as the industry rushes to find solutions to the pandemic, while furthering research in rare and complex diseases. As pharma companies reignite clinical development, streamlining commercialization is crucial in bridging the…
The 10-Year Test: Is It Possible to Plan Launch During Clinical Development?
Time and strategy are keys to launching in an overwhelmed, unpredictable market. Pharmaceutical companies in mid-development of a drug need to look ahead at their launch strategy options and consider what market conditions could look like by the time they’re ready to commercialize their product. By evaluating the value…
Moving Forward in Pharma: Reigniting Revenue for Mature Brands
The world will be moving forward with immeasurable effects from the COVID-19 pandemic, as will the pharmaceutical industry. Fully understanding the impact that the pandemic will have on pharma will take years; however, there are future…
When America Sneezes, the World Catches a Cold: How Changes to U.S. Drug Pricing Will Affect the Globe
Through an intense U.S. election season, there is one issue that patrons of the right and left agreed on: The cost of prescription drugs is viewed as unfair and unsustainable. With President Joe Biden in office,…
How Better Alignment Propels Your Brand’s Success
As pharma companies race to keep up with today’s market, your brand’s team can’t afford to be out of sync. Yet inefficiencies and miscommunications are common throughout the commercialization process — wasting valuable resources, creating confusion among key stakeholders and slowing…
CMS Adopts Automatic Medicare Coverage of Breakthrough Devices
The Centers for Medicare and Medicaid Services (CMS) on January 12 finalized its proposal of Medicare Coverage of Innovative Technology (MCIT), an additional pathway of coverage for breakthrough-designated medical devices, providing timelines and clarifying definitions of…
Emerging 2021 Life Science Priorities
From commercializing high-science therapies to empowering a data-driven patient experience (in the midst of a global pandemic!), we’ve learned that the life sciences industry requires agility, speed and scale. How will 2020 experiences set the emerging…
A Rundown of 2020 Trends in Pharma
As we begin 2021 and vaccines roll out across the globe, it seems that the world is hopeful and eager to move forward from 2020. The COVID-19 pandemic impacted almost every aspect of our lives, wreaking havoc on numerous industries and forcing global companies to re-evaluate their…
EVERSANA is Fighting COVID-19 Through a Growing Number of Client Engagements
The new year began with a light of hope ignited by the long-awaited COVID-19 vaccine. However, a vaccine is only the first step in fighting the pandemic. Healthcare professionals and drug manufacturers must continue to apply…